Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002029054 | SCV002297476 | uncertain significance | Saldino-Mainzer syndrome | 2021-11-30 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with IFT140-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.002%). This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 81 of the IFT140 protein (p.Glu81Asp). |
Fulgent Genetics, |
RCV005017062 | SCV005645317 | uncertain significance | Saldino-Mainzer syndrome; Retinitis pigmentosa 80 | 2024-05-14 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004753470 | SCV005350376 | uncertain significance | IFT140-related disorder | 2024-07-20 | no assertion criteria provided | clinical testing | The IFT140 c.243G>T variant is predicted to result in the amino acid substitution p.Glu81Asp. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0018% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |